Dr. Steven M. GrunbergGet A Free Mesothelioma Guide
Dr. Steven M. Grunberg is a professor of medicine and pharmacology at the University Of Vermont College Of Medicine.
Phone: (802) 656-5457
Address: Division of Hematology/Oncology Given Building E214 89 Beaumont Avenue University of Vermont Burlington, VT 05405
Get Help Contacting This Doctor
Dr. Steven M. Grunberg is a professor of medicine and pharmacology at the University Of Vermont College Of Medicine. He is a full level member of the Vermont Cancer Center and also serves as a clinical researcher. Dr. Grunberg’s interests lie in developmental chemotherapy and early clinical trials of new anti-cancer agents.
After engaging in work that spanned early clinical trials of cytotoxics, biologics, antiemetics, and differentiating agents, Dr. Grunberg’s current projects include developing newer, more effective head, neck and lung cancer strategies. In addition, Dr. Grunberg also maintains a focus on supportive care and symptom management, including pharmacologic interventions, the evaluation of patient and healthcare professional perceptions, and pharmacoeconomic analysis.
Additional Work and Distinctions
Dr. Grunberg also currently serves on the Vermont Cancer Center Protocol Review Committee and Clinical Research Oversight Committee. In addition, he holds the position of editor of the Proceedings of the American Society of Clinical Oncology, is a board member of the Northern New England Clinical Oncology Society, and acts as Treasurer of the Multinational Association of Supportive Care in Cancer. He was also formerly a chair member of the NCI Initial Review Group Subcommittee G (Education).
The University of Vermont explains that Dr. Grunberg was and continues to be part of numerous professional societies, including the following:
International Association for the Study of Lung Cancer
Multinational Association for Supportive Care in Cancer Program Committee, 2002
Board of Directors, 2005-2008
Publishing Committee Chair, 2006-2008
American Society of Clinical Oncology Editor, ASCO Program/Proceedings, 2000-2010
Cancer Education Committee 2003-2006
Program Committee, 1988, 1994, 1998, 1999
Program Subcommittee Chair, 1999
Annual Meeting Session Chair, 1987, 1988, 1998, 1999
Annual Meeting Poster Discussant, 1993, 1999
Annual Meeting Slide Discussant, 1995
Meet the Professor, 2001
Oncology Training Programs Committee, 1990 1992
Subcommittee on Medical Oncology Training Programs, 1989
Special Awards Committee, 1993
Public Issues Committee, 1992 1997, 2000-2003
Health Services Research Committee, 1997-2000
Anti-Emetics Expert Panel, 1996
American Association for Cancer Research Fellow, American College of Physicians Cancer & Leukemia Group B, 1994 – Present
Symptom Management Core Committee
Northern New England Clinical Oncology Society
Board of Directors, 1995-2007
In addition, the University of Vermont College of Medicine explains that Dr. Grunberg has been the author of numerous medical journal publications, including the following:
Grunberg SM, Deuson RR, Mavros P, Hansen M, Cruciani G, Daniele B, DePouvourville G, Rubenstein E, Daugaard G: Incidence and Impact of Nausea/Vomiting with Modern Antiemetics: Perception vs. Reality. Cancer 100:2261-2268, 2004.
Grunberg SM, Dugan MC, Greenblatt MS, Ospina DJ, Valentine JW: Phase I/II Trial of Paclitaxel and Vinorelbine in Advanced Non-Small Cell Lung Cancer. Cancer Invest 23:392-398, 2005.
Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R: Long Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma. Cancer Invest 24:727-733, 2006.
Witherby SM, Butnor KJ, Grunberg SM: Malignant Mesothelioma Following Thoracic Radiotherapy for Lung Cancer. Lung Cancer 57:410-413, 2007.
Grunberg SM: Giving Permission. J Clin Oncol 26:5477-5478, 2008. Grunberg SM, Dugan MC, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M: Effectiveness of a Single-Day Three-Drug Regimen of Dexamethasone, Palonosetron, and Aprepitant for the Prevention of Acute and Delayed Nausea and Vomiting Caused by Moderately Emetogenic Chemotherapy. Support Care Cancer 17:589-594, 2009.
Ettinger DS, Grunberg SM, Hauber AB, Mohamed AF: Evaluation of the Relative Importance of Chemotherapeutic and Antiemetic Efficacy in Various Oncologic Settings. Support Care Center 17:405-411, 2009.
Grunberg SM, Rolski J, Strrausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J: Efficacy and Safety of Casopitant Mesylate, a Neurokinin 1 (NK1)-Receptor Antagonist, in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Cisplatin-Based Highly Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Trial. Lancet Oncol 10:549-558, 2009.
Butnor KJ, Beasley MB, Cagle PT, Grunberg SM, Kong F-M, Marchevsky A, Okby NT, Roggli VL, Suster S, Tazelaar HD, Travis WD: Protocol for the Examination of Specimens from Patients with Primary Non-Small Cell Carcinoma, Small Cell Carcinoma, or Carcinoid Tumor of the Lung. Arch Pathol Lab Med (In Press) 2009.
Grunberg SM, Weeks J, Magnan WF, Herndon J, Naughton ML, Blackwell KL, Wood ME, Christian DL, Perry MC, Dees EC, Reed E, Marshall ME, for Cancer and Leukemia Group B: Determination of Utilities for Control of Chemotherapy-Induced Nausea or Vomiting — CALGB 309801. J Support Oncol (In Press) 2009.
Dr. Grunberg attended Cornell University in Ithaca, New York, graduating with his bachelor’s degree in 1971 and earning his medical degree with the university’s medical college four years later, in 1975. From 1975 until 1976, Dr. Grunberg interned with the University of California Medical Center HC Moffitt Hospital in San Francisco, California. He then undertook a residency position at the University of California Affiliated Hospitals in San Francisco from 1976 until 1978. From 1978 until 1980, Dr. Grunberg then undertook a fellowship at the Sidney Farber Cancer Institute in Boston, Massachusetts, specializing in medical oncology.